PAZOPANIB
Generic: PAZOPANIB
Aurobindo Pharma LimitedManufacturer
ORALRoute
PAZOPANIB HYDROCHLORIDEActive Substance
2024-12-04Original Approval
PAZOPANIB is FDA application ANDA219034, sponsored by EUGIA PHARMA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
MALIGNANT NEOPLASM PROGRESSION
536 reports
2
PRODUCT USE IN UNAPPROVED INDICATION
346 reports
3
DIARRHOEA
328 reports
4
DEATH
317 reports
5
DRUG INEFFECTIVE
283 reports
6
FATIGUE
278 reports
7
DISEASE PROGRESSION
267 reports
8
NAUSEA
228 reports
9
OFF LABEL USE
226 reports
10
HYPERTENSION
194 reports